Floatz logo

CLOPIDOGREL

Ischemic Stroke

Nanfang Hospital, Southern Medical UniversitySmall moleculePhase 4 / ApprovedActive
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
75/ 100
Competitive Position
65/ 100

Competitive context

197 Active assets in the Ischemic Stroke cohort.

Asset / SponsorPhaseRating
Ticagrelor
Sichuan Provincial People's Hospital
Phase 4BBB
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Stanford University
Phase 4BBB
Compound Edaravone
Nanfang Hospital, Southern Medical University
Phase 4BBB
Argatroban
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BBB
Tenecteplase
Hackensack Meridian Health
Phase 4BBB

View all 50 →

Same molecule, other indications

CLOPIDOGREL is also rated in:

myocardial infarctionActive
A
Indicative · Phase 4
81 / 100
View asset →
peripheral arterial diseaseActive
BBB
Indicative · Phase 4
77 / 100
View asset →
transient ischemic attackActive
BBB
Indicative · Phase 4
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →